JP2023514567A5 - - Google Patents
Info
- Publication number
- JP2023514567A5 JP2023514567A5 JP2022548895A JP2022548895A JP2023514567A5 JP 2023514567 A5 JP2023514567 A5 JP 2023514567A5 JP 2022548895 A JP2022548895 A JP 2022548895A JP 2022548895 A JP2022548895 A JP 2022548895A JP 2023514567 A5 JP2023514567 A5 JP 2023514567A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pharmaceutical composition
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026019348A JP2026097829A (ja) | 2020-02-14 | 2026-02-09 | 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976582P | 2020-02-14 | 2020-02-14 | |
| US62/976,582 | 2020-02-14 | ||
| PCT/IB2021/051215 WO2021161270A2 (en) | 2020-02-14 | 2021-02-12 | Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026019348A Division JP2026097829A (ja) | 2020-02-14 | 2026-02-09 | 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514567A JP2023514567A (ja) | 2023-04-06 |
| JP2023514567A5 true JP2023514567A5 (enExample) | 2025-08-05 |
Family
ID=77271772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548895A Pending JP2023514567A (ja) | 2020-02-14 | 2021-02-12 | 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 |
| JP2026019348A Pending JP2026097829A (ja) | 2020-02-14 | 2026-02-09 | 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026019348A Pending JP2026097829A (ja) | 2020-02-14 | 2026-02-09 | 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210253690A1 (enExample) |
| EP (1) | EP4103606A4 (enExample) |
| JP (2) | JP2023514567A (enExample) |
| KR (1) | KR20220141847A (enExample) |
| CN (1) | CN115427444A (enExample) |
| AU (1) | AU2021218265A1 (enExample) |
| BR (1) | BR112022015996A2 (enExample) |
| CA (1) | CA3170677A1 (enExample) |
| IL (1) | IL295545A (enExample) |
| MX (1) | MX2022009987A (enExample) |
| WO (1) | WO2021161270A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024151320A2 (en) * | 2022-07-29 | 2024-07-18 | Curium Us Llc | [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof |
| AU2024317528A1 (en) | 2023-07-31 | 2026-03-05 | Curium Us Llc | [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2205276A4 (en) * | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
| US20170211876A1 (en) * | 2014-06-12 | 2017-07-27 | Hoffmann-La Roche Inc. | Method for selecting antibodies with modified fcrn interaction |
| MX2018003376A (es) * | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| TWI744617B (zh) * | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
-
2021
- 2021-02-12 IL IL295545A patent/IL295545A/en unknown
- 2021-02-12 AU AU2021218265A patent/AU2021218265A1/en active Pending
- 2021-02-12 US US17/175,129 patent/US20210253690A1/en not_active Abandoned
- 2021-02-12 JP JP2022548895A patent/JP2023514567A/ja active Pending
- 2021-02-12 WO PCT/IB2021/051215 patent/WO2021161270A2/en not_active Ceased
- 2021-02-12 EP EP21753729.9A patent/EP4103606A4/en active Pending
- 2021-02-12 CN CN202180028613.4A patent/CN115427444A/zh active Pending
- 2021-02-12 KR KR1020227031763A patent/KR20220141847A/ko active Pending
- 2021-02-12 CA CA3170677A patent/CA3170677A1/en active Pending
- 2021-02-12 MX MX2022009987A patent/MX2022009987A/es unknown
- 2021-02-12 BR BR112022015996A patent/BR112022015996A2/pt not_active Application Discontinuation
-
2023
- 2023-06-16 US US18/210,885 patent/US20240002494A1/en active Pending
-
2026
- 2026-02-09 JP JP2026019348A patent/JP2026097829A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7493569B2 (ja) | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 | |
| Tol et al. | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity | |
| JP2024016177A5 (enExample) | ||
| JP2022534020A (ja) | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 | |
| JP6097888B2 (ja) | 新規使用 | |
| JP2019523295A5 (enExample) | ||
| EP4596046A2 (en) | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha | |
| IL316408A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| JP2020500152A5 (enExample) | ||
| EP3773715A1 (en) | Methods of treating ulcerative colitis | |
| JP2021502349A5 (enExample) | ||
| JP2020535149A5 (enExample) | ||
| JP2021515770A5 (enExample) | ||
| IL310216A (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| JP2020502261A5 (enExample) | ||
| JP2024543885A5 (enExample) | ||
| JP2022536088A5 (enExample) | ||
| RU2011146339A (ru) | Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r | |
| JP2021523138A5 (enExample) | ||
| JP2023544620A5 (enExample) | ||
| JP2022514561A5 (enExample) | ||
| JP2022534794A5 (enExample) | ||
| JP2025515337A5 (enExample) | ||
| JP2024542777A5 (enExample) | ||
| JP2021522241A5 (enExample) |